Skip to main content

Table 2 Pathology and treatment for hepatoid carcinoma of the pancreas

From: Hepatoid carcinoma of the pancreas

  Total Pancreatic head Pancreatic body-tail P value
Histopathology n = 22 n = 9 n = 13 0.205
Pure hepatoid carcinoma 13 (59.1 %) 4 (44.4 %) 9 (69.2 %)  
Mixed with other pathology 9 (40.9 %) 5 (55.6 %) 4 (30.8 %)  
Nonfunctioning NEC 3 (13.6 %) 3 (33.3 %) 0  
Ductal adenocarcinoma 2 (9.1 %) 1 (11.1 %) 1 (7.7 %)  
Malignant glucagonoma 1 (4.5 %) 0 1 (7.7 %)  
Malignant insulinoma 1 (4.5 %) 0 1 (7.7 %)  
Nonfunctioning NET 1 (4.5 %) 1 (11.1 %) 0  
Acinar cell carcinoma 1 (4.5 %) 0 1 (7.7 %)  
Metastasis at diagnosis 8 (36.4 %) 2 (22.2 %) 6 (46.2 %) 0.246
Lymph node metastasis 4 (21.1 %) 1 (14.3 %) 3 (25.0 %) 0.525
Liver metastasis 7 (31.8 %) 2 (22.2 %) 5 (38.5 %) 0.372
Treatment n = 20 n = 8 n = 12 0.670
Surgery Pancreaticoduodenectomy 17 (85.0 %) 7 (87.5 %) 10 (83.3 %)  
Distal pancreatectomy 5 (25.0 %) 5 (62.5 %) 0  
Enucleation 9 (45.0 %) 0 9 (75.0 %)  
Total pancreatectomy 1 (5.0 %) 1 (12.5 %) 0  
Surgery + chemotherapy 2 (10.0 %) 1 (12.5 %) 1 (8.3 %)  
Surgery + TAE 1 (5.0 %) 1 (12.5 %) 0  
Surgery + chemotherapy + TAE 1 (5.0 %) 0 1 (8.3 %)  
Surgery + radiotherapy + TAE 1 (5.0 %) 0 1 (8.3 %)  
No treatment 1 (5.0 %) 0 1 (8.3 %)  
Other 2 (10.0 %) 1 (12.5 %) 1 (8.3 %)  
  1 (5.0 %) 0 1 (8.3 %)  
  1. NEC neuroendocrine carcinoma, NET neuroendocrine tumor, TAE transarterial embolization